门静脉支架置入术治疗良性门静脉主干狭窄所致门静脉高压症
Portal venous stent placement for treatment of portal hypertension caused by benign main portal vein stenosis.
作者信息
Shan Hong, Xiao Xiang-Sheng, Huang Ming-Sheng, Ouyang Qiang, Jiang Zai-Bo
机构信息
Department of Radiology, Changzheng Hospital of the Second Military Medical University, Shanghai 200433, China.
出版信息
World J Gastroenterol. 2005 Jun 7;11(21):3315-8. doi: 10.3748/wjg.v11.i21.3315.
AIM
To evaluate the value of endovascular stent in the treatment of portal hypertension caused by benign main portal vein stenosis.
METHODS
Portal vein stents were implanted in six patients with benign main portal vein stenosis (inflammatory stenosis in three cases, postprocedure of liver transplantation in another three cases). Changes in portal vein pressure, portal vein patency, relative clinical symptoms, complications, and survival were evaluated.
RESULTS
Six metallic stents were successfully placed across the portal vein stenotic or obstructive lesions in six patients. Mean portal venous pressure decreased significantly after stent implantation from (37.3+/-4.7) cm H(2)O to (18.0+/-1.9) cm H(2)O. The portal blood flow restored and the symptoms caused by portal hypertension were eliminated. There were no severe procedure-related complications. The patients were followed up for 1-48 mo. The portal vein remained patent during follow-up. All patients survived except for one patient who died of other complications of liver transplantation.
CONCLUSION
Percutaneous portal vein stent placement for the treatment of portal hypertension caused by benign main portal vein stenosis is safe and effective.
目的
评估血管内支架在治疗良性门静脉主干狭窄所致门静脉高压中的价值。
方法
对6例良性门静脉主干狭窄患者（3例为炎性狭窄，另3例为肝移植术后）植入门静脉支架。评估门静脉压力、门静脉通畅情况、相关临床症状、并发症及生存率的变化。
结果
6例患者均成功在门静脉狭窄或阻塞病变处植入6枚金属支架。支架植入后门静脉平均压力从（37.3±4.7）cm H₂O显著降至（18.0±1.9）cm H₂O。门静脉血流恢复，门静脉高压所致症状消除。无严重的与手术相关的并发症。患者随访1至48个月。随访期间门静脉保持通畅。除1例患者死于肝移植其他并发症外，所有患者均存活。
结论
经皮门静脉支架置入术治疗良性门静脉主干狭窄所致门静脉高压安全有效。
Zotero 插件